Across TCGA pan-cancer cohorts, ADAMTSL5 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ADAMTSL5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ADAMTSL5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ADAMTSL5 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where ADAMTSL5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADAMTSL5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	−1.313	<.001	12	view →
HNSC	All	IV	−1.688	<.001	11	view →
LUAD	All	III,IV	−0.642	<.001	9	view →
LSCC	All	All	−0.354	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ADAMTSL5 RNA expression & survival · all ADAMTSL5 data types